Trial Profile

A phase I/II study of CR-001 in solid tumors.

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 08 Jan 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CR-001-Crescent Biopharma (Primary)
Indications Gastrointestinal cancer; Gynaecological cancer; Non-small cell lung cancer; Solid tumours
Focus Adverse reactions; Proof of concept
Acronyms ASCEND

05 Jan 2026 According to Crescent Biopharma Media Release, the trial expected to initiate in first quarter of 2026, with proof-of-concept data anticipated in first quarter of 2027
05 Jan 2026 According to Crescent Biopharma Media Release, company announced announced regulatory clearances of Investigational New Drug (IND) applications for CR-001, a PD-1 x VEGF bispecific antibody, and CR-003, an integrin beta-6 (ITGB6)-targeted antibody drug-conjugate (ADC), both being developed for the treatment of advanced solid tumors.
04 Nov 2025 According to Crescent Biopharma media release, company anticipate dosing patients of this study in first quarter 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com